Pennystocksupdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 08/29/2013 -- Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) said its trial investigator considered the heart rhythm disorder to be possibly related to the treatment.
The company said in a statement Wednesday that there were no serious adverse events observed in the trial but revised it on Thursday to include the transient atrial fibrillation event that occurred in one patient.
The drug, APD811, was being tested as a treatment for pulmonary arterial hypertension (PAH) - in which arteries of the lungs constrict, forcing the heart to work harder.
In the early-stage trial, 40 healthy volunteers received the drug and 15 received placebo, with the most frequent treatment related adverse events being headache, nausea and jaw pain.
Arena said it planned to start mid-stage trial for the drug in the first quarter of 2014, and the results of the early-stage program led to its decision to proceed with further development of the drug.
The mid-stage development of APD811 will include further exploration of dosing regimens in PAH patients, Arena said.
The company, which made the first obesity drug to be approved in the United States in 13 years, has two other drugs in clinical trials - for treating autoimmune diseases and blood-clot related disorders.
Arena shares dropped 3.63% to $6.45.
Why Should Investors Buy ARNA After The Recent Fall? Find Out Here
Neither Pennystocksupdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Pennystocksupdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. Pennystocksupdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Pennystocksupdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)